AstraZeneca initiates trial for AZD5148 to prevent recurrent Clostridioides difficile infection
AstraZeneca is evaluating AZD5148 for preventing recurrence of Clostridioides difficile infection in adults.
Asset / Drug
Drug and asset intelligence for AZD5148 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.